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Tumor‑Agnostic Treatment for Cancer: When How is Better than Where 
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Abstract 
In the evolving landscape of precision oncology, genomic characterization of tumor has become crucial in order to move 
toward a molecular-based therapy for the vast majority of cancers. Recently, translational research has offered new perspec- 
tives in systemic cancer treatment thanks to the identification of novel oncogenic targets and the development of new targeted 
therapies, followed by the latest applications of genomic sequencing. Simultaneously, next-generation sequencing (NGS) has 
expanded its accessibility, being incorporated into clinical studies at the time of the initial screening, disease progression, and 
often in longitudinal monitoring of molecular changes. Consequently, new potentially targetable molecular alterations have 
been identified in several different types of tumors, leading to the development of tumor-agnostic treatments. Being highly 
selective for specific molecular alterations, these drugs are active against different subtypes of oncogene-addicted cancers. 
Three of these drugs—pembrolizumab [an anti-programmed death 1 (PD-1) monoclonal antibody (MAb)], larotrectinib [a 
pan-tropomyosin receptor tyrosine kinase (TRK) inhibitor], and entrectinib [a pan-TRK, anaplastic lymphoma kinase (ALK) 
and ROS-1 inhibitor]—received US FDA approval in 2017, 2018, and 2019, respectively. In this article, we critically review 
the clinical studies responsible for FDA approval and the most recently updated results. We then discuss the benefits and 
limitations of these new methodological approaches, paying particular attention to the largest precision medicine master 
protocol, NCI-MATCH. Among the benefits, there are the increased chances of offering targeted therapies for patients with 
specific alterations identified in different types of tumors. Among the limitations, we highlight that the same driver mutation 
may require different therapeutic strategies in different types of cancers. Additionally, the complex study design undeniably 
requires a dynamic strategy to enroll patients with considerable economic and managerial efforts. 
 
1 Introduction 
 
The evolving landscape of precision oncology requires a 
comprehensive knowledge of the molecular mechanisms 
underlying oncogenic pathway alterations. Genomic char- 
acterization of cancer has become crucial in order to offer 
highly effective treatments and avoid unnecessary adverse 
events to non-responders. Fortunately, in recent years, trans- 
lational research has off ed new perspectives in systemic 
cancer treatment, first with the identification of novel onco- 
genic targets [e.g. REarranged during Transfection proto- 
oncogene (RET), tropomyosin receptor tyrosine kinase 
   (TRK), fibroblast growth factor receptor (FGFR), etc.] and 
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the development of new targeted therapies, and, second, 
by improving the methods and applications of genomic 
sequencing [1, 2]. 
Next-generation sequencing (NGS), with its short- and 
long-read applications, has expanded its accessibility as a 
result of the improved output promptness, the increasing 
availability of molecularly targeted drugs, and its cost-effec- 
tive approach [3]. 
 
 
  
Key Points 
 
Three drugs—pembrolizumab, larotrectinib, and entrec- 
tinib—received US FDA approval in 2017, 2018, and 
2019, respectively. 
New paradigms have been developed in clinical cancer 
research, in order to design clinical trials more suitable 
for treatment needs. 
  
 
Simultaneously with these advances, clinical trials have 
become more dependent on tumor molecular profiling. As a 
result, these sequencing techniques have been incorporated 
into clinical studies, at the time of the initial screening, dis- 
ease progression, and often in longitudinal monitoring of 
molecular changes [4–6]. 
New potentially targetable molecular alterations have 
been identified in several different types of tumors, leading 
to the development of so-called tumor-agnostic treatments 
[2, 6]. Being highly selective for specific molecular altera- 
tions, these drugs are active against diff ent subtypes of 
oncogene-addicted cancers [6]. 
On 23 May 2017, the US FDA approved pembrolizumab, 
a monoclonal antibody (MAb) that binds to the programmed 
death 1 (PD-1) receptor, as the fi  t tumor-agnostic treat- 
ment. The indication included the treatment of patients with 
unresectable or metastatic, microsatellite instability-high 
(MSI-H) or mismatch repair-deficient (dMMR) solid tumors 
that have progressed after prior standard treatment and who 
have no other satisfactory treatment option, or with MSI-H 
or dMMR colorectal cancer that has progressed after treat- 
ment with a fluoropyrimidine, oxaliplatin, and irinotecan [7]. 
Larotrectinib, the second tumor-agnostic drug, was 
approved by the FDA on 26 November 2018. Larotrectinib 
is indicated for adult and pediatric patients with unresectable 
or metastatic solid tumors harboring a neurotrophic tyros- 
ine receptor kinase (NTRK) gene fusion without a known 
acquired resistance mutation, and who have progressed after 
previous treatment or have no satisfactory standard treatment 
options [8]. 
On 15 August 2019, the FDA approved the third tumor- 
agnostic treatment, entrectinib, a potent multikinase pan- 
TRK inhibitor with additional activity against anaplas- 
tic lymphoma kinase (ALK), and ROS-1. The indication 
included the treatment of pediatric (≥ 12 years of age) and 
adult patients with solid tumors harboring NTRK gene 
fusion without a known acquired resistance mutation, 
metastatic disease, or where surgical resection is likely to 
result in severe morbidity, progression of disease after prior 
treatment, and/or no satisfactory standard treatment options. 
Entrectinib also received FDA approval for adult patients 
with metastatic NSCLC harboring ROS1 rearrangement 
[9]. The characteristics of these three drugs are shown in 
Table 1. 
 
 
2  Neurotrophic Receptor Tyrosine Kinase 
(NTRK) 
 
The TRK family includes TRKA, encoded by the gene 
NTRK1; TRKB, encoded by NTRK2; and TRKC, encoded 
by NTRK3. These receptors are involved in nervous system 
development and homeostasis, playing an important role in 
the regulation of neuronal differentiation and survival. The 
TRK receptors are also widely expressed in non-neural tis- 
sues, including lung, bone, pancreatic β-cell, and monocytes. 
Three ligands specifically bind, with high affinity, at least 
one of the TRK family members: nerve growth factor (NGF) 
prevalently binds TRKA; brain-derived neurotrophic factor 
(BDNF) and neurotrophin 4 (NT-4) prevalently bind TRKB; 
and neurotrophin 3 (NT-3) prevalently binds TRKC. After 
ligand binding to one of the wild-type TRK family members, 
the activation of multiple intracellular signaling pathways 
occurs, including the MAPK, PI3K, and PKC pathways. 
NTRK gene fusions, which are the most common events 
conferring oncogenic TRK activation, lead to the transcrip- 
tion of a chimeric oncoprotein. The product of the fusion 
is characterized by constitutive activation regardless of the 
presence of the specific ligands. Since 1982, when the first 
gene fusion was identified, more than 50 new fusion partners 
have been characterized, and they are heterogeneously asso- 
ciated with various types of cancer. These rearrangements 
are detected at frequencies higher than 90% in rare tumor 
types, such as secretory breast carcinoma, mammary analo- 
gous secretory carcinoma of salivary glands (MASC), and 
infantile fibrosarcomas, and frequencies of 70–85% in con- 
genital mesoblastic nephroma [10, 11]. In contrast, they are 
detected at frequencies of 5–25% in other types of cancer, 
such as papillary thyroid cancer, Spitzoid neoplasms, pedi- 
atric gliomas, and wild-type gastrointestinal solid tumors 
(GISTs), and < 5% in other cancers, such as non-small cell 
lung cancer (NSCLC), cholangiocarcinoma, colorectal can- 
cer, astrocytoma, melanoma, and head and neck cancer [10, 
11]. 
Entrectinib and larotrectinib are currently FDA-approved 
for the treatment of cancer harboring NTRK gene fusions. 
Larotrectinib is a potent, highly selective inhibitor of all 
TRK members, with half maximal inhibitory concentra- 
tion (IC50) values of 5–11 nM. Using a large panel of non- 
TRK enzymes, larotrectinib also showed inhibitory activity 
against TNK2 at an approximately 100-fold higher concen- 
tration [8]. Entrectinib is active against all TRK members, 
ALK, and ROS-1, with IC50 values of 0.1–2 nM, and also 
inhibits JAK2 and TNK2, with IC50 values > 5 nM [9]. 
Three main trials evaluated the efficacy and safety 
of larotrectinib in NTRK fusion-positive patients with 
various tumor types. A phase I study enrolled adults 
(LOXO-TRK-14001, NCT02122913), a phase I–II study 
enrolled children (SCOUT, NCT02637687), and a phase 
II study enrolled adolescents and adults (NAVIGATE, 
NCT02576431) (Table 2). The fi t 55 patients enrolled 
across the three studies were included in a combined analysis 
with objective response rate (ORR) as the primary endpoint. 
Overall, 22% of patients had a salivary gland tumor, 20% had 
a soft tissue sarcoma, 13% had an infantile fi osarcoma, 
and 9% had a thyroid cancer. The analysis demonstrated the 
 
 
 
   
 
Table 1 First three tumor-agnostic treatments that received US FDA approval 
Drug Molecular formula Spectrum of activity  Date of 
US FDA 
approval 
 
 
US FDA indication 
 
 
Pembrolizumab [7]  C6534H10004N1716O2036S46    Anti-PD-1 MAb 23 May 
2017 
Pediatric and adult patients with unresectable or metastatic, 
MSI-H or dMMR solid tumors that have progressed 
after prior standard treatment and who have no other 
satisfactory treatment options, or with MSI-H or dMMR 
colorectal cancer that has progressed after treatment with 
a fluoropyrimidine, oxaliplatin, and irinotecan 
Larotrectinib [8] C21H22F2N6O2 Pan-TRK inhibitor 26 November  Pediatric and adult patients with solid tumors that have 
 
 
 
 
Entrectinib [9] C31H34F2N6O2 Pan-TRK, ALK and 
ROS-1 inhibitor 
2018 
 
 
 
 
15 August 
2019 
NTRK gene fusion without a known acquired resistance 
mutation, metastatic disease, or where surgical resection 
is likely to result in severe morbidity, and have progressed 
after treatment or have no satisfactory standard treatment 
options 
Pediatric (≥ 12 years of age) and adult patients with solid 
tumors that have NTRK gene fusion without a known 
acquired resistance mutation, metastatic disease, or where 
surgical resection is likely to result in severe morbidity, 
and have progressed after treatment or have no satisfac- 
tory standard treatment options 
Adults with metastatic NSCLC whose tumors are ROS- 
1-positive 
 
 
dMMR mismatch repair-deficient tumor, MAb monoclonal antibody, MSI-H high microsatellite instability, NTRK neurotrophic tyrosine receptor 
kinase, PD-1 programmed death 1, TRK tropomyosin receptor tyrosine kinase, ALK anaplastic lymphoma kinase, NSCLC non-small cell lung 
cancer 
 
 
remarkable activity of larotrectinib, regardless of tumor type 
or specifi TRK fusions, with an ORR of 75%, including 
13% of patients who obtained a complete response (CR). 
Rapid and prolonged tumor responses were observed, with 
a median time to response of 1.8 months and a median 
duration of response not reached. Among all patients, the 
progression-free survival (PFS) rate at 12 months was 55%. 
Of note, radical surgery was performed in two patients 
with locally advanced infantile fibrosarcoma, since a tumor 
shrinkage under treatment occurred [8, 12] 
Three multicenter, single-arm trials (ALKA-372–001, 
STARTRK-1, and STARTRK-2) explored the activity of 
entrectinib (Table 2) in patients with a wide range of unre- 
sectable or metastatic solid cancers harboring NTRK gene 
fusions. Data from the fi t 54 patients enrolled were col- 
lected to assess efficacy and safety. An ORR of 57.4% was 
reported, with CR in 7.4% of patients and a probability of 
no progression or death of 45% at 1 year [9, 13]. 
In more detail, ALKA-372-001 and STRTRK-1 were 
two phase I trials that enrolled a total of 119 patients, 
of whom 60 were rearranged in NTRK, ROS1, or ALK. 
Among the group of patients without rearrangements, 53 
had point mutations, amplifications, copy number variants, 
or insertions/deletions, whereas 6 had no known alterations. 
Responses were only observed in patients harboring ALK, 
 
ROS1, or NTRK rearrangements, with the exception of one 
patient with neuroblastoma harboring an ALK F1245V 
mutation. Of note, no responses were observed among 
patients with ROS1 or ALK rearrangement who were pre- 
viously treated with crizotinib, ceritinib, or alectinib. In the 
analysis restricted to TKI-naïve patients treated with 600 mg 
daily, entrectinib showed activity on all three patients har- 
boring an NTRK fusion, i.e. SQSTM1-NTRK1 in NSCLC, 
ETV6-NTRK3 in MASC, and LMNA-NTRK1 in colorectal 
cancer. Stable disease (SD) with remarkable clinical benefit 
was reported in one patient with a glioneuronal tumor har- 
boring the BCAN-NTRK1 rearrangement. In these trials, 
responses were also observed in ROS1-rearranged NSCLC 
and ALK-rearranged NSCLC, renal cell carcinoma, and 
colorectal cancer. Entrectinib also showed encouraging 
activity in the central nervous system (CNS), both on meta- 
static lesions and primary brain tumors [14]. Moreover, in a 
phase I/Ib trial (STARTRK-NG), entrectinib demonstrated 
remarkable clinical activity in patients ≤ 20 years of age with 
refractory CNS or solid tumors harboring NTRK, ROS1, or 
ALK rearrangements [15]. 
The activity of entrectinib is currently being evaluated 
in a multicenter, phase II basket study (STARTRK-2 trial, 
NCT02568267), which is enrolling patients with NTRK, 
ROS1, or ALK fusion-positive cancers. 
  
 
 
 
 
 
 
 
 
 
Table 2 Summary of the main prospective trials that were crucial for US FDA approval of tumor-agnostic treatments 
 
 
Trial Phase   Treatment Study population No. of patients   Primary endpoint ORR (%)  PFS OS 
 
Combined analysis of 
LOXO-TRK-14001, 
SCOUT, and NAVI- 
GATE [8, 12] 
I–II Larotrectinib Pediatric and adult patients 
with advanced NTRK 
fusion-positive tumor 
55 ORR 75 12-month PFS: 55% NR 
Pooled analysis of ALKA- 
372–001, STARTRK-1, 
I–II Entrectinib Unresectable or metastatic 
solid cancers of 10 tumor 
54 DLT, MTD, RP2D, ORR 57.4 11.2 months 20.9 months 
and STARTRK-2 [9, 13] types harboring NTRK 
gene fusions 
 
Cohorts A and C from II Pembrolizumab 200 mg Cohort A: dMMR meta- 10 Immune-related ORR and 40 20-week immune- NR 
KEYNOTE-016 [21]  q3w static colorectal cancer, 7 20-week immune-related 71 related PFS: 78%  
   after standard treatment  PFS rate  20-week immune-  
   failure  20-week immune-related  related PFS: 67%  
   Cohort C: dMMR  PFS rate    
metastatic non-colorectal 
cancer, after standard 
treatment failure 
 
Cohort A from KEY- II Pembrolizumab 200 mg MSI-H metastatic colorec- 
NOTE-164 [23] q3w tal cancer, after at least 
two chemotherapy lines, 
including fluoropyrimi- 
dine, oxaliplatin, and 
61 ORR 33 12-month PFS: 34% 12-month OS: 72% 
irinotecan      
Selected patients from 
KEYNOTE-158 [24] 
II Pembrolizumab 200 mg 
q3w 
MSI-H/dMMR cancers 
of 27 tumor types other 
than colorectal, after at 
least one prior regimen 
233 ORR 34.3 4.1 months 23.5 months 
dMMR mismatch repair-deficient tumor, MSI-H high microsatellite instability, NR not reached, NTRK neurotrophic tyrosine receptor kinase, OS overall survival, ORR objective response rate, 
PFS progression-free survival, q3w every 3 weeks 
D
. Lavacch
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3 Microsatellite Instability 
 
MSI-H tumors are included in those harboring a dMMR 
system. These cancers are characterized by hypermutabil- 
ity of specific tandem DNA repeat sequences as a result of 
impaired DNA repair. The frequency of MSI-H signature 
is extremely variable across cancer types. Analyzing large 
cohorts of exomes and genomes across diff ent cancer 
types, the incidence of MSI-H was 16–19% among colon 
adenocarcinomas, 5–9% among rectal adenocarcinomas, 
28–31% among uterine corpus endometrial carcinomas, 
19–22% among gastric adenocarcinomas, 4–5% among 
adrenocortical carcinomas, and < 4% in other types of can- 
cers. Overall, MSI-H tumors account for 3–4% of all cancers 
[16, 17]. These tumors most commonly arise from somatic 
mutations in sporadic cases; less commonly, they may be 
an expression of germline mutations within hereditary syn- 
dromes (e.g. Lynch syndrome). 
There are several mechanisms responsible for the MSI-H 
phenotype, including mutation in the MLH1, MSH2, MSH3, 
MSH6, and PMS2 genes, hypermethylation of the MLH1 
promoter and the epigenetic inactivation of MSH2, plus the 
downregulation of genes involved in mismatch repair sys- 
tems by microRNAs [17, 18]. 
Harboring 10–100 times more mutations than mismatch 
repair-proficient (pMMR) tumors, dMMR tumors have been 
associated with high sensitivity to immunotherapy [19, 
20]. The high concentration of tumor-infiltrating lympho- 
cytes (TILs), specifically CD3+ and CD8+, within MSI-H 
tumors offers a possible explanation for the high immuno- 
genicity [19]. The high mutational load, characteristic of 
dMMR tumors, has been thought to be responsible for high 
expression of neoantigens on the surface of tumor cells [19, 
20]. In addition, high expression levels of PD-1, cytotoxic 
T-lymphocyte-associated protein 4 (CTLA-4), and lympho- 
cyte-activation gene 3 (LAG-3) on TILs, and PD-ligand 1 
(PD-L1) on tumor cells, have been found as a result of an 
immune-reactive microenvironment [19]. 
In the phase II KEYNOTE-016 trial (Table 2), 41 patients 
with stage IV disease were treated with pembrolizumab 
after standard treatment failure [21]. The study popula- 
tion included dMMR colorectal cancer (cohort A), pMMR 
colorectal cancer (cohort B), and dMMR endometrial, 
small bowel, gastric cancer or cholangiocarcinoma (cohort 
C). The evaluation of MMR status was carried out using 
the MSI Analysis System (Promega Corporation, Madi- 
son, WI, USA), with a specifi analysis of several tandem 
DNA repeat sequences involved in microsatellite instabil- 
ity. Among patients with dMMR tumors, 24 times more 
somatic mutations were observed on average compared with 
patients with pMMR tumors. In addition, in these patients, 
immunohistochemical analysis showed a higher density of 
CD8+ lymphoid cells and PD-L1 expression. 
The primary endpoints for cohorts A and B were met, 
with an immune-related ORR of 40% in cohort A compared 
with 0% in cohort B, and 20-week immune-related PFS rates 
of 78% and 11%, respectively. Likewise, the primary end- 
point for cohort C was met, with an immune-related PFS at 
20 weeks of 67% and an ORR of 71%. Disease control rate 
(DCR) was 90% in cohort A and 71% in cohort C. Interest- 
ingly, all patients with dMMR tumors without Lynch syn- 
drome had an objective response when compared with 27% 
of ORR in patients with Lynch syndrome. Median PFS and 
overall survival (OS) in cohort B were 2.2 and 5 months, 
respectively. In contrast, median PFS was 5.4 months in 
cohort C, and was not reached in cohort A. In addition, 
the median OS was not reached in both cohorts [21]. In an 
updated analysis of this study, ORRs were 52% and 54% 
in patients with MSI-H/dMMR colorectal cancer and other 
cancer types, respectively, with no signifi diff ence 
between patients with or without Lynch syndrome [22]. 
Similar results were obtained in cohort A of the phase 
II KEYNOTE-164 trial (Table 2). Among 61 previously 
treated colorectal cancer patients with MSI-H/dMMR, a 
remarkable activity of pembrolizumab was observed in all 
effi outcomes (ORR of 33%, 1-year PFS of 34%, and 1-
year OS of 72%) [23]. 
In addition, data from another three multicohort trials 
(KEYNOTE-012, KEYNOTE-028, and KEYNOTE-158) 
(Table 2), including small groups of MSI-H/dMMR patients 
(n = 6, n = 5, and n = 19, respectively), were considered for 
FDA approval of pembrolizumab in patients with MSI-H/ 
dMMR cancer [7]. 
More specifically, the multicohort KEYNOTE-158 trial 
evaluated the activity of pembrolizumab in patients with 
different types of cancer who progressed after prior standard 
treatments. An updated analysis of 223 patients with MSI-H/ 
dMMR non-colorectal cancer from all cohorts, including 
cohort K, which was specifi for MSI-H/dMMR patients, 
showed an ORR of 34.3%, with a median time to response 
of 2.1 months. This trial confirmed the activity of pembroli- 
zumab in these molecularly selected patients, with a median 
PFS of 4.1 months and estimated 2-year PFS and OS rates 
of 29.3% and 48.9%, respectively [24]. 
Consistent with these results, the phase II CheckMate142 
trial showed a clear benefi off ed by the combination of 
nivolumab and ipilimumab in previously treated patients 
with MSI-H/dMMR colorectal cancer. In this cohort, ORR 
was 55% and DCR for at least 12 weeks was 80%, with 
12-month PFS and OS rates of 71% and 85%, respectively. 
This study was crucial for FDA approval of ipilimumab in 
combination with nivolumab for the treatment of this molec- 
ularly selected patient population previously treated with a 
fluoropyrimidine, oxaliplatin, and irinotecan [25]. 
[Digitare qui] [Digitare qui] [Digitare qui] 
 
 
4 New Approaches in Drug Development 
 
In the era of precision medicine, clinical research must be 
able to promptly transpose the advances in translational 
research, adjusting the usual designs of the clinical studies, 
in order to move toward a molecularly guided therapy for 
most cancers. In response to these changes, the need was 
felt to fi new paradigms in clinical cancer research that 
could be more suitable for treatment needs, fully exploiting 
the potential of tools for genome sequencing [1–5]. Master 
protocols have recently been developed for this purpose. 
The patient is initially screened to detect multiple potential 
molecular targets simultaneously. Once the driver mutation 
has been identified, the patient receives the specific targeted 
therapy within a clinical substudy. Thanks to this approach, 
the risk of screening failure is signifi    y reduced and 
the patient’s chances of receiving specifi treatment have 
increased. Consequently, the number of patients enrolled 
within clinical trials may increase and the scattering of 
patients within different studies with concurrent active enrol- 
ment may be reduced. 
A basket trial is an example of a master protocol, involv- 
ing diff ent types of cancer, in which patients with the 
same druggable molecular alteration are enrolled. In con- 
trast, an umbrella trial enrolls patients with the same primary 
tumor class or location. After an initial screening in which 
molecular alterations are detected, patients are assigned to 
the appropriate subtrial to receive specific targeted therapies 
[5]. In this context, NCI-MATCH is a phase II study with 
an attractive design, and could be a model for generating 
further trials. In the first phase, patients are screened using 
NGS, after which approximately one-third of patients could 
probably be included in one of the 25 single-arm substudies 
(subsequently expanded to 35), in case a druggable mutation 
is detected. The primary endpoint is ORR [26]. In the last 
few years, preliminary results have been presented (Table 3). 
Among patients with dMMR endometrial, prostate, breast, 
and other types of cancer, nivolumab has shown moderate 
effi , with an ORR and DCR of 36% and 57%, respec- 
tively [27]. The selective FGFR inhibitor AZD4547 has 
demonstrated modest activity in patients with FGFR ampli- 
fication, mutation, or fusion, with an ORR and DCR of 5% 
and 51%, respectively [28]. The pan-AKT inhibitor capiva- 
sertib demonstrated promising activity in patients diagnosed 
with tumors harboring AKT1 E17K mutation (ORR 23% 
and DCR 69%) [29]. Moderate clinical activity of ado-trastu- 
zumab emtansine was observed in patients with human epi- 
dermal growth factor receptor 2 (HER2)-amplified cancers 
of different types, excluding breast and gastric cancers (ORR 
5.6% and DCR 52.6%) [30]. In cohort I, the PI3K inhibi- 
tor taselisib showed a 6-month PFS rate of 27% in patients 
with activating mutations in PIK3CA, although no partial 
response (PR) or CR were reported. Interestingly, the muta- 
tional co-occurrence rate was 67% [31]. Among patients 
with deleterious phosphatase and tensin homolog (PTEN) 
mutations or deletions, only 4.5% obtained a response with 
the PI3K β-selective inhibitor GSK2636771 [32]. Afatinib, 
an irreversible pan-HER inhibitor, showed disappointing 
activity in terms of ORR and 6-month PFS rates (2.7% 
and 11%, respectively) in HER2-mutated patients (exclud- 
ing NSCLC), while a significant response was observed in 
one patient with adenocarcinoma of extramammary Paget’s 
skin disease [33]. Among patients with CCND1–3-amplified 
cancers, a DCR of 38.9% and ORR of 0% were observed 
with the cyclin-dependent kinase 4 and 6 inhibitor palboci- 
clib [34]. The Wee1 kinase inhibitor AZD1775 has shown 
modest clinical activity in heavily pretreated patients with 
BRCA1–2 mutations. Only 3.2% of patients had a clear 
response, with an overall 6-month PFS rate of 19% [35]. 
The combination of dabrafenib and trametinib has shown 
promising activity in patients with BRAF-V600E/K mutated 
cancers, excluding melanoma, colorectal, and thyroid cancer. 
In this cohort, ORR was 33.3% and the 6-month PFS rate 
was 70.6% [36]. 
Some other alterations (e.g. BRCA mutations, isoci- 
trate dehydrogenase [IDH] mutations, and FGFR aberra- 
tions) may be predictive of the clinical benefi  of specifi 
targeted therapies, and have been identifi as promising 
tumor-agnostic markers [37, 38]; however, tumor-agnostic 
markers must offer a similar therapeutic benefit on various 
types of cancer to be considered reliable. BRCA1/2 muta- 
tions are one the most studied biomarkers for tumor-agnostic 
treatment, as evidenced by the FDA approval of poly(ADP- 
ribose) polymerase (PARP) inhibitors for the treatment of 
breast, ovarian, pancreatic, and, in the future, prostate can- 
cer. Although BRCA1/2 mutations have been detected in a 
wide range of cancer types, the extent of the clinical benefit 
provided by PARP inhibitors in patients with BRCA-mutant 
tumors differs according to tumor histology. In contrast, 
other biomarkers, such as the homologous recombination 
deficiency score, could better predict the efficacy of PARP 
inhibition in patients with BRCA-mutated cancers [37]. 
Several clinical trials are currently evaluating new 
targeted therapies for molecularly selected patients with 
various solid tumors. The phase II LODESTAR trial 
(NCT04171700) is studying the efficacy of rucaparib 
in patients with deleterious alterations in homologous 
recombination repair (HRR) genes. Cohort A is enrolling 
patients with mutations in BRCA1–2, PALB2, RAD51C, 
or RAD51D, whereas the exploratory cohort B is enroll- 
ing patients with mutations in BARD1, BRIP1, FANCA, 
NBN, RAD51, or RAD51B [40]. Another PARP inhibi- 
tor, IDX-1197, is currently under evaluation in the phase 
   
 
Table 3 Summary of the main preliminary results from the NCI-MATCH master protocol 
 
Reference Treatment Study population No. of patients ORR (%) DCR (%) Survival outcomes 
Azad et al. [27] Nivolumab (anti-PD-1) dMMR non-colorectal 42 
cancers of various types 
36 57 18-month PFS rate: 31.4% 
Median OS: 17.3% 
(e.g. endometrioid endo- 
metrial adenocarcinoma, 
prostate adenocar- 
cinoma, and uterine 
 
 
Chae et al. [28] 
 
AZD4547 (FGFR inhibi- 
carcinosarcoma) 
Tumors with FGFR 
 
50 
 
5 
 
51 
 
6-month PFS rate: 17% 
 tor) amplification, mutation, 
or fusion (e.g. breast, 
urothelial, and endome- 
trial) 
    
Kalinsky et al. [29] Capivasertib (pan-AKT 
inhibitor) 
Tumors with AKT1 E17K 
mutation (e.g. breast, 
and endometrioid 
adenocarcinoma) 
35 23 69 6-month PFS rate: 52% 
Jhaveri et al. [30] Ado-trastuzumab emtan- 
sine (HER2-targeted 
antibody–drug conju- 
gate) 
HER2-amplified tumors, 
excluding breast and 
gastric cancers 
36 5.6 52.6 6-month PFS rate: 23.6% 
Krop et al. [31] Taselisib (PI3-kinase 
inhibitor) 
Tumors with activating 
mutations in PIK3CA 
65 0 NR 6-month PFS rate: 27% 
Janku et al. [32] GSK2636771 (PI3K Arm N: tumors with 22 4.5 36.5 Median PFS: 1.8 months in 
 β-selective inhibitor) PTEN mutation/deletion 34 0 37.5 both arms 
Arm P: tumors with loss 
of PTEN 
 
Bedard et al. [33] Afatinib (pan-HER inhibi- 
tor) 
HER2-mutated patients, 
excluding NSCLC 
40 2.7 NR 6-month PFS rate: 11% 
Clark et al. [34] Palbociclib (cyclin- 
dependent kinase 4 and 
6 inhibitor) 
CCND1-3 amplified 
cancers 
40 0 38.9 Median PFS: 1.8 months 
Kummar et al. [35] AZD1775 (Wee1 kinase 
inhibitor) 
Tumors with mutations in 
BRCA 1–2 
33 3.2 NR 6-month PFS rate: 19% 
Salama et al. [36] Dabrafenib (BRAF 
inhibitor) and trametinib 
(MEK inhibitor) 
Tumors with BRAF 
V600E/K mutations, 
excluding melanoma, 
and colorectal and 
thyroid cancer 
35 33.3 NR Median PFS: 9.4 months 
DCR disease control rate, dMMR mismatch repair-deficient tumor, FGFR fibroblast growth factor receptor, HER2 human epidermal growth fac- 
tor receptor 2, NR not reported, NSCLS non-small cell lung cancer, OS overall survival, ORR objective response rate, PD-1 programmed death 1, 
PFS progression-free survival, PTEN phosphatase and tensin homolog 
 
Ib/IIa VASTUS trial (NCT04174716), which is enroll- 
ing patients with HRR mutation [41]. In another ongo- 
ing trial (NCT03017521), patients with PI3K/AKT gene 
aberration are receiving a highly selective AKT inhibi- 
tor, TAS-117 [42]. The ongoing phase II trial CAPTURE 
(NCT03297606) has been designed to simultaneously 
evaluate 13 regimens (olaparib, dasatinib, nivolumab 
plus ipilimumab, axitinib, bosutinib, crizotinib, palbo- 
ciclib, sunitinib, temsirolimus, erlotinib, trastuzumab 
plus pertuzumab, vemurafenib plus cobimetinib, vismo- 
degib) for patients with solid cancers harboring drug- 
gable alterations such as VEGFR1–3, BCR-ABL, SRC, 
ALK, ROS-1, MET, POLE, POLD, BRCA1–2, FGFR1–3, 
BRAF-V600, PTCH1, etc. [43]. The phase II FUZE trial 
(NCT03834220) is evaluating the efficacy of a pan-FGFR 
inhibitor debio 1347 in patients with FGFR1–3 gene rear- 
rangements [44]. 
Although these new approaches have offered several advan- 
tages in the personalized treatment of cancer, they showed 
some limitations. First, the same driver mutation may require 
diff ent therapeutic strategies in diff ent types of cancer. The 
BRAF-V600E mutation, for example, occurring in approxi- 
mately 50% of melanomas and 5–15% of colorectal cancers, 
has different rates of response to targeted therapies in these 
cancer types [51]. Excellent results have been obtained with 
BRAF inhibition and, better yet, with the combined BRAF 
[Digitare qui] [Digitare qui] [Digitare qui] 
 
 
and MEK inhibition in melanoma [45, 46]. In contrast, mono- 
therapy with BRAF inhibitors has failed in colorectal cancer 
treatment [47]. The main mechanism responsible for the lim- 
ited efficacy of BRAF inhibitors in colorectal cancer is the 
feedback activation of the EGFR pathway [48]. Triple com- 
bination strategies involving both BRAF and MEK inhibitors 
plus anti-EGFR MAbs or chemotherapy have been shown to 
improve the efficacy outcomes [49]. In addition, conducting 
precision medicine trials, such as basket, umbrella, or other 
master protocols, is challenging since researchers have to 
address several study problems and research questions simul- 
taneously, and have to pay attention to the increased risk of 
false positive results. Being limited in sample size, the results 
of each single arm are obtained after a long period of time, 
with considerable economic and managerial efforts. Finally, 
the complex study design undeniably requires a dynamic strat- 
egy to enroll patients, and considerable flexibility to open and 
close subprotocol arms [52, 53]. 
 
5 Conclusions 
 
In the last few years, the treatment strategy for the vast major- 
ity of cancers has become highly dependent on molecular pro- 
fi   leading to the introduction of tumor-agnostic treatments 
(i.e. pembrolizumab, larotrectinib, and entrectinib). New trial 
designs have been developed to increase the chances of offer- 
ing targeted therapies for patients with specific alterations 
identified in different types of tumors. Although promising, 
this approach needs to be further studied to definitively be 
considered practice changing. 
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